Cytopia's CYT997 for treatment of solid tumors well-tolerated in phase 1 study

By Lisa Kerner

Charlotte, N.C., June 26 - Cytopia Ltd. said dose levels of CYT997 administered in a phase 1 trial for the treatment of solid tumors have been well-tolerated by patients, with no identified dose-limiting toxicities.

A total of 16 patients have received 46 doses of CYT997 across six incremental dose levels to date, according to a company news release.

Dose escalation will continue until two or more patients within a dose level exhibit a dose-limiting toxicity, the company said. The trial is expected to continue into the third quarter of 2006.

The clinical study is also designed to determine the safety, tolerability and maximum tolerated dose of CYT997 given as a 24-hour intravenous infusion every three weeks.

Cytopia said it plans a phase 1 clinical trial investigating the oral administration of CYT997 in Australia by the end of the year.

In addition, the company is planning phase 2 studies including the application of CYT997 in highly vascular cancers with poor prognosis such as hepatoma.

Cytopia is a Melbourne, Australia, biotechnology company focused on the discovery and development of drugs to treat cancer, immune disorders and cardiovascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.